Pulmonx Corporation (LUNG)

NASDAQ: LUNG · IEX Real-Time Price · USD
15.85
-0.05 (-0.31%)
Jun 24, 2022 4:00 PM EDT - Market closed
-0.31%
Market Cap 588.30M
Revenue (ttm) 49.96M
Net Income (ttm) -51.39M
Shares Out 37.12M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE 28.33
Dividend n/a
Ex-Dividend Date n/a
Volume 1,287,344
Open 16.28
Previous Close 15.90
Day's Range 15.70 - 16.66
52-Week Range 13.84 - 45.81
Beta n/a
Analysts Buy
Price Target 30.75 (+94.0%)
Earnings Date Aug 2, 2022

About LUNG

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based q... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Oct 1, 2020
Employees 253
Stock Exchange NASDAQ
Ticker Symbol LUNG
Full Company Profile

Financial Performance

In 2021, Pulmonx's revenue was $48.42 million, an increase of 47.91% compared to the previous year's $32.73 million. Losses were -$48.66 million, 51.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is 30.75, which is an increase of 94.01% from the latest price.

Price Target
$30.75
(94.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported ...

Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the comp...

Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will r...

Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported...

Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...

Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High?

The mean of analysts' price targets for Pulmonx Corporation (LUNG) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...

Primecap Pumps Up Pulmonx Position

Media-shy investment firm Primecap Management revealed earlier this week it boosted its stake in Pulmonx Corp. ( LUNG , Financial), impacting the equity portfolio by 0.03%.

Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference

REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) --  Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the comp...

Pulmonx to Participate at Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 24.32% and -0.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today r...

Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale

Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exch...

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/C...

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

Other symbols: AXSMVRTX

Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investo...

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option

Pulmonx Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today r...

Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Hea...

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe C...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication o...